Two things before anyone answers the substance.
First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.
Two things before anyone answers the substance.
First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.
This follows post #8 rather than contradicting it.
P-values and significance: p<0.05 means the data would be surprising if the null hypothesis were true, not that the null hypothesis is false. A non-significant p-value does not mean "no effect".
Relative risk and odds ratios: both compare the rate in one group to the rate in another. Relative risk is easier to understand. Odds ratios are standard in many analyses but can be misinterpreted.
Power and sample size: a study might be too small to detect a real effect (low power). Sample size calculations help determine how many participants are needed to detect an effect of a given magnitude.
Multiplicity and multiple comparisons: if you test many hypotheses, the chance of finding a false positive by random chance increases. That is why pre-specifying the primary hypothesis matters.
post #92 is right about the mechanism and I think understates the practical bit.
I disagree with the reply above, and I think the disagreement is substantive rather than terminological.
The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.
This follows post #96 rather than contradicting it.
I disagree with the reply above, and I think the disagreement is substantive rather than terminological.
The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.
For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
Number needed to treat: how many people need to be treated to prevent one bad outcome or achieve one good outcome. More intuitive than relative risk reduction.
Read the full topic (167 posts)
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
About the Statistics category
Effect sizes, intervals, multiplicity, and the difference between absent and undetected. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its…
|
+4 | 8 | 2.3k | 7mo |
|
Measurement error in home scales, with a worked standard deviation
Measurement error in home scales, with a worked standard deviation Writing it up because I had to work it out twice and would rather nobody else did. Comparing SURPASS-4 ( Lancet , 2021) with STEP 1 ( N Engl…
|
+26 | 31 | 4.3k | 4mo |
|
Regression to the mean in progress reports
On the subject in the title: Regression to the mean in progress reports Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it before posting; the discussion…
|
+30 | 34 | 49k | 12mo |
|
What a confidence interval means, from scratch
What a confidence interval means, from scratch — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen STEP 8 ( JAMA , 2022) cited in support of a claim I do not…
|
2 | 2.6k | 2mo | |
|
[2026 update] Correlation in a self-tracked dataset: what it can support
Posting this under the heading it deserves: Correlation in a self-tracked dataset: what it can support Everything below is what sits behind that. I have seen SURMOUNT-4 ( JAMA , 2024) cited in support of a…
|
2 | 31k | 6h |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
The most common factual error about semaglutide on the internet — what changed since
The most common factual error about semaglutide on the internet — what changed since — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with STEP 1 ( N…
|
+42 | 46 | 1.7k | 5mo |
|
Immortal time bias in a claims-database study — one year on
Posting this under the heading it deserves: Immortal time bias in a claims-database study — one year on Everything below is what sits behind that. Comparing SURPASS-2 ( N Engl J Med , 2021) with SURMOUNT-1 (…
|
+41 | 46 | 3.7k | 22h |
|
Retatrutide's phase 2 heart-rate signal and how to think about it
On the subject in the title: Retatrutide's phase 2 heart-rate signal and how to think about it Working notes rather than a conclusion. I have seen PIONEER 6 ( N Engl J Med , 2019) cited in support of a claim…
|
+19 | 23 | 20k | 7mo |
|
Second pass at: Journal club: LEADER as the historical anchor
Posting this under the heading it deserves: Second pass at: Journal club: LEADER as the historical anchor Everything below is what sits behind that. Comparing SCALE ( N Engl J Med , 2015) with SURPASS-2 ( N…
|
+75 | 81 | 2k | 2y |
|
Peak-to-trough ratio at steady state for a weekly agent
On the subject in the title: Peak-to-trough ratio at steady state for a weekly agent Working notes rather than a conclusion. I would like to understand what this number means before I repeat it anywhere. A…
|
+58 | 64 | 9.7k | 2mo |